denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Hematology Disease Topics & Pathways:
Lymphoid Leukemias, ALL, Biological therapies, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Therapies, Lymphoid Malignancies, Transplantation
Description:
Most pediatric patients with ALL achieve durable long-term remission with chemotherapy alone, however, some experience refractory or multiply relapsed diseases requiring further definitive therapy. HSCT has a long-established track record in ALL with favorable overall survival rates. More recently, CAR T-cells have been a transformational addition to the tools available for the treatment of ALL. While there are generally accepted criteria for selecting patients for definitive therapy, currently, physician judgement and institutional preference primarily drive the decision on HSCT vs CAR T. This educational session will explore the criteria to be considered for using HSCT vs CAR T in high-risk ALL including patient’s individual risk, prior complications/toxicities/organ functions, graft sources available, institutional expertise, and access to cellular therapy.
Dr. Nirali Shah will discuss delayed toxicities following CAR T-cells, outline the management of delayed toxicity in the post-CAR T-cell setting, weigh current approaches to vaccination and monitoring of immune reconstitution post CAR T-cells and shed light on active efforts in the study of late effects, including monitoring of second malignant neoplasms.
Dr. Alice Bertaina will discuss HSCT considerations for ALL. The recent emergence of CD19+ CAR T therapy as another viable treatment option for R/R ALL offers unique considerations for the selection of definitive therapy in these patients. This talk will outline the current state of the art of HSCT for ALL and will discuss relevant considerations for selecting a definitive therapy in ALL.
Dr. Stephen Gottschalk will review the role of hematopoietic cell transplantation (HSCT) to sustain remission post CD19-CAR T cell therapies and discuss 2nd genetic modifications to improve CAR T cell persistence and prevent the emergence of antigen loss variants.
Dr. Nirali Shah will discuss delayed toxicities following CAR T-cells, outline the management of delayed toxicity in the post-CAR T-cell setting, weigh current approaches to vaccination and monitoring of immune reconstitution post CAR T-cells and shed light on active efforts in the study of late effects, including monitoring of second malignant neoplasms.
Dr. Alice Bertaina will discuss HSCT considerations for ALL. The recent emergence of CD19+ CAR T therapy as another viable treatment option for R/R ALL offers unique considerations for the selection of definitive therapy in these patients. This talk will outline the current state of the art of HSCT for ALL and will discuss relevant considerations for selecting a definitive therapy in ALL.
Dr. Stephen Gottschalk will review the role of hematopoietic cell transplantation (HSCT) to sustain remission post CD19-CAR T cell therapies and discuss 2nd genetic modifications to improve CAR T cell persistence and prevent the emergence of antigen loss variants.